FDA accepts Amgen's submission and files Biologics License Application for denosumab
Amgen Inc. today announced that the FDA has accepted Amgen's submission and filed a Biologics License Application for denosumab, an investigational RANK Ligand inhibitor
Amgen today announced that it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.